Streptozocin Shortage: Current FDA Status Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has listed Streptozocin Powder for Solution as currently in shortage, affecting oncology treatments, with one manufacturer reporting availability.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on May 9, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Streptozocin.
What's in Shortage
The drug in shortage is Streptozocin Powder, For Solution, with the brand name ZANOSAR. This is a powder for solution dosage form used in oncology. The current status is listed as current in the FDA database, with the shortage first posted on 07/12/2022 and last updated on 05/06/2026.
Which Manufacturers Are Affected
The affected manufacturer is ESTEVE PHARMACEUTICALS, S.A., which reports the product as available. Their presentation is Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01). Contact information for this manufacturer is USSZTOrders@esteve.com.
Why There's a Shortage
No specific reason for the shortage has been provided in the source data.
What Patients Should Do
Patients who rely on this medication should speak with their pharmacist or healthcare provider to check availability and discuss options. It may be helpful to contact the manufacturer directly using the provided information. Remember, patients should always consult their healthcare provider for personalized advice and not make changes to their treatment without professional guidance.
Source
This information is sourced from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,192 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to May 9, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.